Industry news
Mitsubishi Tanabe will acquire NeuroDerm Ltd and with it ND 0612 a proposed treatment for Parkinsons disease
Mitsubishi Tanabe Pharma will acquire all of the outstanding shares of NeuroDerm Ltd for $1 billion. The lead product of NeuroDerm is ND 0612, liquid levodopa and carbidopa combination which has commenced Phase III trials in the US and EU to treat Parkinsons disease and which is expected to launch in 2019.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
